Global Lung Cancer Screening Software Market

Market Snapshot

• Market Size (2025): USD 1.475 Billion
• Projected Market Size (2035): USD 5.38 Billion
• Compound Annual Growth Rate (CAGR): 13.81%
• Largest Regional Market: North America
• Fastest Growing Region: Asia Pacific
• 3^rd Largest Region: Middle East and Africa
• Base Year: 2025
• Historical Period: 2021–2024
• Forecast Period: 2026–2035

According to Decision Advisors, the Global Lung cancer screening software Market Size is expected to grow from USD 1.475 billion in 2024 to USD 5.38 billion by 2035, at a CAGR of 13.81% during the forecast period 2025-2035. Global lung cancer screening software market is expected to experience substantial growth over the forecast period due primarily to growing use of AI in diagnostics, a rise in diagnostic tests for lung cancer, and worldwide increases in early lung cancer detection programs. The global AI-based diagnostic tools market will expand due to advances in imaging technologies; increased digitalization of healthcare; and continued investments in lung cancer screening programs.

 

Market Overview/ Introduction

The global lung cancer screening software market refers to the industry developing software tools that assist in early detection of lung cancer using medical imaging, especially low-dose CT scans. These solutions use AI and analytics to identify nodules, support diagnosis, and improve screening efficiency in healthcare facilities. Lung cancer screening software is a medical software solution designed to analyze imaging data, especially low-dose CT scans, to help detect lung nodules and early signs of lung cancer. It uses technologies such as artificial intelligence and computer-aided detection to assist radiologists in diagnosis, risk assessment, and patient screening management. In December 2025,  AZmed launched AZnod, an AI-powered CT analysis tool under the Rayscan product line after receiving CE marking. The solution detects and characterizes lung nodules between 3–30 mm on CT scans, delivering standardized measurements and structured reports to support lung cancer screening programs and radiologists. In 2025, Coreline Soft partnered with Oatmeal Health to jointly develop an AI-based lung cancer screening solution combining nodule detection and malignancy prediction. The collaboration targets the U.S. market, seeking FDA clearance and expansion within the estimated $1.6 billion annual screening market. In February 2025, The Lung Cancer Screening and Prevention Act of 2025 (H.R. 1406) was introduced to expand Medicare coverage for additional FDA-approved lung cancer screening tests. The bill directs Centers for Medicare & Medicaid Services to set payment limits, potentially supporting adoption of innovative AI-based screening software tools.

 

• In March 2026: The European Commission opened a call to establish a network of AI-powered advanced screening centres across European Union. The initiative aims to accelerate AI use in early disease detection, including cancer, with participation open until April 10, 2026.

 

• In February 2026: Goa launched the country’s first AI-enabled lung cancer screening pilot, planning to review over 200,000 chest X-rays by 2026. The initiative, announced by Vishwajit Rane, integrates AI analysis with routine diagnostics in government hospitals to support earlier lung cancer detection.

 

• In 2026: National Cancer Grid and Koita Centre for Digital Oncology, with the IndiaAI Mission, joined the India AI Summit 2026 to promote AI-driven oncology innovation and collaboration across healthcare.  

 

Notable Insights: -

1. Asia-Pacific holds the largest regional market share approximately 38.14% in the global lung cancer screening software market.
2. North America is the fastest growing region market share approximately 34.86% in the global lung cancer screening software market.
3. By type, the computer-assisted screening software segment held a dominant position with 21% in terms of market share in 2025.
4. By deployment mode, cloud-based solutions segment is the dominating accounting for over 20% of the global market share in 2025.
5. By product, lung nodule computer-aided detection segment is the dominating accounting for market is approximately 22%.
6. By end user, hospital segment held a dominant position market is approximately 19%.
7. The market is likely to achieve a valuation of USD 5.38 billion by 2035.

 

What is role of technology in grooming the market?

Technology plays a major role in grooming the lung cancer screening software market by improving early detection, diagnostic accuracy, and workflow efficiency. Advanced tools such as artificial intelligence (AI), machine learning, and computer-aided detection allow automated analysis of CT scans and identification of lung nodules. The market is expected to grow from about USD 3 billion in 2025 to around USD 4.16 billion by 2030, at a CAGR of nearly 6.7%, supported by AI-driven screening innovations. Additionally, AI can reduce radiologist interpretation time by up to 40% and lower false positives by 20–30%, encouraging adoption across hospitals and screening programs worldwide.

 

How is Recent Developments Helping the Market?

Recent developments in lung cancer screening software, largely driven by advancements in artificial intelligence (AI), machine learning, and 3D imaging technologies, are significantly accelerating market growth, with the market projected to expand at a CAGR of about 6.9% through 2030. These innovations improve the accuracy of early lung cancer detection by enabling automated identification and characterization of lung nodules in low-dose CT scans. In addition, AI-based tools help reduce radiologist workload by automating image analysis, reporting, and patient follow-up processes. Healthcare providers are increasingly shifting toward preventive screening and monitoring of high-risk populations, which further increases demand for advanced screening software solutions across hospitals and diagnostic centers worldwide.

 

Market Drivers

The lung cancer screening software market is primarily driven by the increasing global burden of lung cancer and the growing emphasis on early detection to reduce mortality rates. Lung cancer remains one of the leading causes of cancer-related deaths worldwide, encouraging healthcare systems to adopt advanced screening technologies. The rising use of low-dose CT (LDCT) screening programs is significantly boosting demand for specialized software that can analyze imaging data efficiently. Another major driver is the rapid advancement of artificial intelligence (AI) and machine learning technologies, which enhance the accuracy of lung nodule detection and assist radiologists in diagnosing cases more quickly. These technologies reduce interpretation time, minimize diagnostic errors, and improve clinical decision-making. Additionally, increasing healthcare digitalization, government-supported cancer screening initiatives, and investments in healthcare IT infrastructure are contributing to market growth. Hospitals and diagnostic centers are adopting advanced screening platforms to manage large volumes of imaging data, streamline workflows, and improve patient outcomes, further accelerating the expansion of the lung cancer screening software market.

 

Restrain

Key restraint in the lung cancer screening software market is the high cost of implementation and integration with existing hospital IT systems and imaging infrastructure. Limited awareness and lack of skilled professionals in some regions also slow adoption. Additionally, concerns regarding data privacy, regulatory approvals, and variability in screening guidelines can create challenges for widespread deployment of these advanced software solutions.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the lung cancer screening software market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

Top Companies in Global Lung cancer screening software Market

1. Nuance Communications, Inc.
2. Eon
3. Koninklijke Philips N.V.
4. Siemens Healthineers AG
5. PenRad Technologies, Inc.
6. MagView
7. Voxel Cloud
8. FUJIFILM Holdings Corporation
9. Medtronic
10. GE HealthCare Technologies Inc.
11. Qure.ai
12. Optellum
13. Lunit
14. Canon Medical Systems Corporation
15. Volpara Solutions Limited

 

Government Initiatives

Country	Key Government Initiatives
UK	From February 2025, the NHS Targeted Lung Health Check (TLHC) Programme will become known as the NHS Lung Cancer Screening Programme.
US	The Health Tech Investment Act being considered in the United States Senate proposes a Medicare reimbursement pathway for AI-enabled medical devices, aiming to encourage innovation and accelerate adoption of advanced healthcare technologies.
China	China released updated national lung cancer screening guidelines recommending low-dose computed tomography (LDCT) for early detection among high-risk populations, aiming to improve diagnosis rates and reduce lung cancer mortality nationwide.

 

Study on the Supply, Demand, Distribution, and Market Environment of Energy Management Systems Market

Lung cancer screening software supplies include a number of AI-based, cloud-based, and on-premise solutions supplied by companies including Nuance Communications (Nuance), Siemens Healthineers (Siemens), Qure.ai, and GE HealthCare. Companies continually perform research and development to develop advanced imaging analysis, such as nodule detection capabilities. The market for lung cancer screening software is growing due to the rise in the number of people diagnosed with lung cancer, heightened concern about early detection, government screening programs, and the growing acceptance of low-dose CT (computed tomography) programs, particularly in hospitals and diagnostic centers. Lung cancer screening software is distributed through vendor direct sales, or through partnerships or authorized resellers, as well as by means of cloud platforms. This arrangement enables a wide audience to access the solutions and integrate them easily within their company’s existing information technology infrastructure. Rapid technological advances and innovations, the integration of artificial intelligence, regulatory approval by both the US Food & Drug Administration (FDA) and the Conformité Européenne (CE), and the continued growth of the digital health market represent important trends affecting the lung cancer screening software market. Nevertheless, high implementation costs and privacy issues related to data security are significant barriers to the continued expansion of the market.

 

Price Analysis and Consumer Behaviour Analysis

The cost of lung cancer screening software depends on the software's features, how it is delivered, and whether it has AI capabilities. Typically, cloud-based and AI support systems cost more because they use advanced imaging analysis, predictive algorithms, and can generate reports in real time; however, traditional, on-premise software tends to have a lower cost but offers minimal automation. As hospitals and diagnostic centers seek flexible adoption of screening software, subscription-based models and pay-per-scan payment options are becoming more popular. When it comes to consumer behavior, accuracy, workflow efficiency, regulatory compliance, and integration with current IT systems impact purchasing decisions. When deciding on lung cancer screening software, hospitals and oncology centers look for products that provide the best chance of detecting the disease at an early stage, reduce the workload of radiologists, and allow for reimbursement-friendly reporting. The adoption of new software is higher in areas where government regulations support the use of new technology, AI familiarity is widespread, and a good framework exists for providing healthcare.

 

Market Segmentation

The lung cancer screening software market share is classified into type, deployment mode, product, and end user  

 

• The computer-assisted screening software segment dominated the market in 2024, and is projected to grow at a substantial CAGR of approximately 21% during the forecast period.

Based on the type, the lung cancer screening software market is divided into computer-assisted screening software and traditional screening software. Among these, the computer-assisted screening software segment dominated the market in 2024, and is projected to grow at a substantial CAGR of approximately 21% during the forecast period. It is due to their use of AI (Artificial Intelligence) and advanced techniques for analysing images, computer-assisted screening programs have the upper hand in detecting lung nodules reliably and accurately when initiated during the early phase of disease progression. They also provide radiologists with an opportunity to increase efficiency with regard to diagnosis, as well as a potential reduction in diagnostic errors. In fact, this segment was a leader in the market in 2024 

 

• The cloud-based solutions segment accounted for the largest share in 2024, and is anticipated to grow at a significant CAGR of approximately 20 % during the forecast period.

Based on the deployment mode, the lung cancer screening software market is divided into cloud-based solutions, on-premise solutions, and web-based solutions. Among these, the cloud-based solutions segment accounted for the largest share in 2024, and the market was primarily comprised of cloud-based solutions, and these solutions were expected to continue to grow at a compound annual growth rate of nearly 20% during the predicted timeframe due to the increasing need for scalable Healthcare IT infrastructures, remote access to Health Information, secure storage of patient’s medical records, and additional integration of Diagnostic Imaging Systems into the Cloud.  

 

 

• The lung nodule computer-aided detection software segment dominated the market in 2024, and is projected to grow at a substantial CAGR of approximately 22% during the forecast period.

Based on the product, the lung cancer screening software market is divided into radiology solutions, patient management software, nodule management software, data collection & reporting, patient coordination & workflow, lung nodule computer-aided detection, pathology & cancer staging. Among these, in 2024, computer-aided detection (CAD) software for lung nodules accounted for the largest share of the total market size and is expected to see a significant growth rate (CAGR) of approximately 22% over the forecast period due to continued implementation of low dose CT screening programs and the need for precise detection of lung cancer in its early stages.

 

• The hospitals segment dominated the market in 2024, and is projected to grow at a substantial CAGR of approximately 19% during the forecast period.

Based on the end user, the lung cancer screening software market is divided into hospitals, oncology centres, ambulatory surgical centres, diagnostic imaging centres, and others. Among these, the hospitals were the leading segment for the overall market growth that will continue through the forecast period with an impressive CAGR approximately 19%. This rapid growth rate can be attributed to an increase in patient volume and access to advanced imaging technology. Additionally, hospitals are incorporating software for screening into their respective hospital systems, as well as taking part in various government-supported initiatives for lung cancer screenings.

 

Strategies to Implement for Growth of the Market in Non-Leading Regions

Growth in non-leading regions the stakeholders in this region need to implement methods that will enhance healthcare infrastructure and increase national lung cancer screening programs to accelerate market growth. More funding for cloud-based technology and artificial intelligence diagnostic software will assist in achieving earlier diagnoses. Governments and healthcare organizations should develop initiatives to promote awareness, which includes supporting favourable reimbursement policies. Developing collaborations between hospitals, research institutions, and technology companies will further stimulate innovation, increase access to screenings, and promote widespread utilization of screening software for lung cancer in emerging healthcare markets.

 

Regional Segment Analysis of the Lung cancer screening software Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

Asia Pacific is anticipated to hold the largest share of the lung cancer screening software market over the predicted timeframe.

Asia Pacific is anticipated to hold the largest share of the lung cancer screening software market over the predicted timeframe. The Asia Pacific lung cancer screening software market is projected to experience rapid growth over the projected period due to the increase in lung cancer cases, increased investment in health care, and an increase in the use of advanced imaging technologies. The Asia Pacific lung cancer screening software market was worth an expected CAGR of approximately 38.14% from 2024 to 2032. This rapid growth is driven by growing screening initiatives, a large elderly population, and the increasing use of artificial intelligence (AI)-based diagnostic tools in countries such as China, Japan, and India, making it one of the fastest-growing regions of lung cancer screening software worldwide.

 

North America is expected to grow at a rapid CAGR in the lung cancer screening software market during the forecast period. The lung cancer screening software market will experience exponential growth at a compound annual growth rate (CAGR) of almost 34.86% over the projected time frame. This immense growth can be attributed to increases in the use of artificial intelligence (AI)-enabled diagnostic imaging solutions through the adoption of new technologies & improvements to currently existing medical imaging tools; coupled with new lung cancer screening programs being implemented all over North America - especially in the U.S. and Canada. Lastly, the introduction of new methods for early detection of various kinds of cancers along with advancements made so far towards the development of digital medical imaging systems can also create further demand for lung cancer screening software.

 

Middle East and Africa are the 3^rd largest region to grow in the lung cancer screening software market during the region. The Middle East and Africa (MEA) are the third-largest regional market for lung cancer screening software, driven by growing awareness of early lung cancer detection, increasing healthcare investments, and adoption of advanced diagnostic technologies. Countries such as the UAE, Saudi Arabia, and South Africa are expanding screening programs and integrating AI-based imaging solutions in hospitals and diagnostic centers, supporting market growth. MEA is expected to witness steady adoption through 2035.

 

Future Market Trends in Global Lung cancer screening software Market: -

1. Increasing Adoption of AI-Powered Screening Software

Market growth will be fueled by the ongoing integration of Artificial Intelligence (AI) and computer-aided diagnostic systems. The lung cancer screening software industry is expected to achieve an average (CAGR) of approximately 6.9% over the 2025–2030 period due to the development of new imaging technologies as well as automated diagnostic equipment.

 

2. Expansion of Global Screening Programs and Early Detection Initiatives

Various nations around the world are attempting to lower lung cancer death rates and get patients diagnosed earlier through expanding their lung cancer screening programs. As a result, there has been tremendous demand from healthcare providers to have advanced screening software that can collect and manage the large amount of imaging and patient data. The lung cancer screening software market should grow to nearly $45 million by 2030, driven chiefly by an increasing awareness of the disease, better access to healthcare and more national public health initiatives aimed primarily at high-risk groups, such as older smokers and aged people. With continued expansion of national lung cancer screening policies, there will likely be a substantial increase in the need for efficient screening technologies.  

 

3. Strong Long-Term Market Growth and Digital Healthcare Transformation

Convenient RTD cocktails and premixed beverages are gaining popularity, especially among younger consumers seeking portable and easy-to-consume alcoholic drinks. This segment is expected to experience significant growth in the coming years.

 

Recent Development

In February 2026, Median Technologies announced that eyonis LCS, an AI-based lung cancer screening device, delivers 93.3% sensitivity and 92.4% specificity in low-dose CT analysis. U.S. authorization and the NT-APC 1508 reimbursement pathway are expected to support nationwide screening expansion for 14.5 million eligible individuals.

 

In February 2026, RevealDx announced that the U.S. Food and Drug Administration cleared RevealAI-Lung, an AI-based software that characterizes lung nodules using a malignancy similarity index to support radiologists’ decisions. Validated on more than 1,500 patients, the solution integrates with PACS systems and is reimbursable by Medicare.

 

In November 2025, Yashoda Hospital, with Qure.ai and AstraZeneca, launched an AI-enabled Lung Nodule Clinic. Over 17,000 chest X-rays analyzed identified 960 nodules, with 77 patients referred for CT scans, improving early detection of lung cancer and other diseases.

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decision Advisors has segmented the lung cancer screening software market based on the below-mentioned segments:  

 

Global Lung cancer screening software Market, By Type

• Computer-Assisted Screening Software
• Traditional Screening Software

 

Global Lung cancer screening software Market, By Deployment Mode

• Cloud-Based Solutions
• On-Premise Solutions
• Web-Based Solutions

 

Global Lung cancer screening software Market, By Product

• Radiology Solutions
• Patient Management Software
• Nodule Management Software
• Data Collection & Reporting
• Patient Coordination & Workflow
• Lung Nodule Computer-Aided Detection
• Pathology & Cancer Staging

 

Global Lung cancer screening software Market, By End User

• Hospitals
• Oncology Centers
• Ambulatory Surgical Centers
• Diagnostic Imaging Centers
• Others

 

Global Lung cancer screening software Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

 

Frequently Asked Questions (FAQ)

1. What are the key cybersecurity measures implemented in lung cancer screening software to protect patient data?
While the report discusses AI and cloud-based solutions, it does not detail the cybersecurity frameworks. Hospitals and providers increasingly require encryption, secure cloud storage, and compliance with HIPAA or GDPR standards to safeguard sensitive imaging and patient information.

 

2. How do reimbursement policies differ across emerging markets for lung cancer screening software?
The report mentions Medicare and some regional initiatives but lacks details on reimbursement in emerging regions. Variations in local health insurance coverage, government programs, and private payers influence adoption rates in countries such as India, Brazil, and South Africa.

 

3. What are the environmental and energy considerations of deploying AI-based lung cancer screening software?
The report does not discuss energy consumption. High-performance computing for AI image analysis may increase energy use, necessitating optimized algorithms, energy-efficient servers, or cloud-based solutions with sustainable practices.

 

4. How does interoperability with existing hospital information systems impact adoption?
Integration with PACS, EMRs, and hospital IT infrastructure is crucial but not deeply addressed in the report. Software that ensures seamless interoperability reduces workflow disruptions and accelerates clinician adoption.

 

5. Are there training programs available for radiologists to effectively use AI-based lung cancer screening software?
The report mentions AI adoption but does not cover training. Structured educational programs and certifications help radiologists interpret AI outputs accurately, improve diagnostic confidence, and enhance early detection efficiency.